《半日總結》恆指跌292點 藥明生物挫11% 港交所跌逾5%
美債孳息上升推低美股,納指隔晚(4日)跌0.8%。港股早市下跌。恆指低開39點後跌幅擴大,半日跌292點或1.8%,報16,353點;國指跌82點或1.4%,報5,621點;恆生科技指數跌76點或2%,報3,683點。大市半日成交總額591.61億元,滬、深港通南下交易半日淨流入12.68億及4.09億元人民幣。
科技股方面,內地11月共批87款國產網絡遊戲,網易(09999.HK)「世界之外」在列,惟網易早市跌4.7%。阿里(09988.HK)跌0.8%報70.25元,騰訊(00700.HK)、美團(03690.HK)、小米(01810.HK)、京東(09618.HK)及快手(01024.HK)跌2.2%至2.7%,百度(09888.HK)跌3.4%。此外,中軟(00354.HK)、美圖(01357.HK)及聯想集團(00992.HK)跌逾6%。手機部件股丘鈦(01478.HK)及舜宇(02382.HK)各跌5.3%及4.3%。
電動車股蔚來(09866.HK)獲准在內地生產電動車,股價升4.1%,比亞迪(01211.HK)逆升1.6%。其他消費股下滑,百威亞太(01876.HK)及泡泡瑪特(09992.HK)跌逾5%,百勝中國(09987.HK)及海底撈(06862.HK)跌逾4%,康師傅(00322.HK)及中國旺旺(00151.HK)跌3.4%。名創優品(09896.HK)傳遭高層減持,股價挫19.7%。
金融股方面,港交所(00388.HK)及友邦(01299.HK)各跌5.3%及4.5%,中國平安(02318.HK)、國壽(02628.HK)、建行(00939.HK)及工行(01398.HK)跌1.6%至2%,匯控(00005.HK)跌0.08%報59.65元。據報多間內地商業銀行目前未收到白名單相關文件,指名單僅屬參考。內房股合景泰富(01813.HK)跌6.1%,龍湖(00960.HK)、融創中國(01918.HK)、富力(02777.HK)及雅居樂(03383.HK)跌3%至3.5%,物管股華潤萬象(01209.HK)跌3.2%。
藥明生物(02269.HK)早市復牌跌11%報29.5元,該股遭多間大行下調目標價。藥明康德(02359.HK)跌2.5%。金價升穿2,100美元後倒跌,招金(01818.HK)及中國黃金國際(02099.HK)跌逾3%,紫金(02899.HK)跌2.2%。國泰(00293.HK)97.5億元向政府回購對方持有半數優先股,股價升0.4%。
魏橋紡織(02698.HK)大股東每股3.5元提私有化,該股半日彈高89.5%報3.24元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.